DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Oral Nadolol for the Treatment of Adults With Mild Asthma

Information source: Invion, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Asthma

Intervention: nadolol (Drug)

Phase: Phase 1/Phase 2

Status: Completed

Sponsored by: Invion, Inc.

Official(s) and/or principal investigator(s):
Richard A Bond, PhD, Principal Investigator, Affiliation: University of Houston

Summary

The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness.

Clinical Details

Official title: An Open-Label, Dose-Escalating, Study to Evaluate the Safety, Efficacy and Tolerability of Oral Nadolol for the Treatment of Adults With Mild Asthma

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: safety

Secondary outcome: Airway hyper-responsiveness

Eligibility

Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Pre-bronchodilator FEV1 80% or greater than the predicted value.

- PC20 FEV1 ≤4 mg/ml on methacholine challenge test.

- Blood Pressure ≥ 100/65mm Hg.

- Pulse rate ≥ 60 beats/min.

- No significant health issues.

- Non-smoker or X-smoker < 10 pack/year.

Exclusion Criteria:

- History of upper/lower respiratory tract infection or asthma exacerbation within 6

weeks of first baseline visit.

- Currently diagnosed with chronic obstructive pulmonary disease (COPD).

- Used any oral or inhaled corticosteroids within 4 weeks of the first baseline visit.

Locations and Contacts

Baylor College of Medicine, Houston, Texas 77030, United States
Additional Information

Related publications:

Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, Dickey BF, Parra S, Ruoss S, Shardonofsky F, O'Connor BJ, Page C, Bond RA. The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study. Pulm Pharmacol Ther. 2008;21(1):134-41. Epub 2007 Jul 17.

Nguyen LP, Lin R, Parra S, Omoluabi O, Hanania NA, Tuvim MJ, Knoll BJ, Dickey BF, Bond RA. Beta2-adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2435-40. doi: 10.1073/pnas.0810902106. Epub 2009 Jan 26.

Starting date: January 2007
Last updated: February 2, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017